ImmunityBio (IBRX) Total Liabilities (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Total Liabilities of $1.5 billion for Q1 2026, up 69.5% year-over-year from $894.2 million in Q1 2025, and up 51.35% quarter-over-quarter from $1.0 billion in Q4 2025.
ImmunityBio (IBRX) Total Liabilities (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Total Liabilities for 13 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 69.5% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 69.5% YoY), while the FY2025 annual figure was $1.0 billion, up 14.97% from the prior year.
- Total Liabilities advanced to $1.5 billion in Q1 2026 per IBRX's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $1.5 billion in Q1 2026 and bottomed at $727.1 million in Q1 2022.
- Historically, Total Liabilities has averaged $967.3 million across 5 years, with a median of $936.4 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 93.4% — and 2024, when it retreated 20.11%.
- ImmunityBio's Total Liabilities stood at $812.2 million in 2022, then soared by 34.26% to $1.1 billion in 2023, then retreated by 20.11% to $871.1 million in 2024, then grew by 14.97% to $1.0 billion in 2025, then soared by 51.35% to $1.5 billion in 2026.
- Business Quant data shows IBRX's Total Liabilities at $1.5 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 1.67 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.67 Bn |
| Mar 31, 2026 | 1.52 Bn |
| Dec 31, 2025 | 1.00 Bn |
| Sep 30, 2025 | 1.04 Bn |
| Jun 30, 2025 | 971.90 Mn |
| Mar 31, 2025 | 894.24 Mn |
| Dec 31, 2024 | 871.06 Mn |
| Sep 30, 2024 | 1.11 Bn |
| Jun 30, 2024 | 1.14 Bn |
| Mar 31, 2024 | 1.09 Bn |
| Dec 31, 2023 | 1.09 Bn |
| Sep 30, 2023 | 843.06 Mn |
| Jun 30, 2023 | 936.41 Mn |
| Mar 31, 2023 | 875.12 Mn |
| Dec 31, 2022 | 812.18 Mn |
| Sep 30, 2022 | 782.02 Mn |
| Jun 30, 2022 | 739.69 Mn |
| Mar 31, 2022 | 727.14 Mn |
| Dec 31, 2021 | 712.82 Mn |
| Sep 30, 2021 | 404.37 Mn |